Core Viewpoint - The company, Jiukang Biotechnology, has evolved from a代理商 to a leading player in the IVD (in vitro diagnostics) industry in China, focusing on innovation and precision diagnosis to drive future growth [2][3]. Group 1: Company Development - Jiukang Biotechnology started as an代理商 for an international IVD brand and quickly gained recognition, becoming a service supplier for the national quality control products [3]. - The company has maintained a strong client base, with over 70% of top-tier hospitals in China being loyal customers [3]. - The company has significantly increased its R&D investment, with R&D accounting for 21% of sales revenue in the first three quarters of 2025, up from 14% in the same period of 2024 [3]. Group 2: Product Innovation - R&D efforts are focused on new products in areas such as pathology, chemiluminescence, and coagulation, leading to an increase in medical device registrations and patents [4]. - The company has launched new products, including a high-speed fully automated chemiluminescence immunoassay analyzer and a biochemical analyzer, enhancing its competitive edge in the market [4]. - Jiukang's first AI project, a prostate cancer AI interpretation software, has been developed and validated, with plans to expand into smart pathology products [4]. Group 3: Strategic Partnerships - The company aims to become a platform enterprise in the IVD sector, collaborating with leading international firms to leverage their strengths and expand into global markets [5]. - A strategic partnership with Abbott began in 2013, allowing Jiukang to share its patented processes for global product production, resulting in profit-sharing [6]. - In 2020, a significant partnership with China National Pharmaceutical Group (Sinopharm) was established, enhancing sales channels and accelerating growth, with Sinopharm becoming the largest shareholder [6]. Group 4: Industry Trends - The IVD industry in China is rapidly developing, with significant growth potential driven by medical reform and innovation [7]. - The industry is expected to undergo a transformation towards high-quality upgrades, with a focus on value competition rather than price competition [7]. - Emerging technologies such as molecular diagnostics and AI-assisted diagnostics are anticipated to become core competitive advantages, with an emphasis on domestic alternatives in high-end markets [7].

Group 1 - The company forecasts a net profit attributable to shareholders of the parent company for 2025 to be between RMB 40 million and RMB 48 million, representing a year-on-year decrease of 62.23% to 68.52% compared to the previous year [2] - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between RMB 26 million and RMB 32 million, reflecting a year-on-year decline of 68.23% to 74.19% [2] - The previous year's net profit attributable to shareholders of the parent company was RMB 127.07 million, with a net profit after deducting non-recurring gains and losses of RMB 100.73 million [4] Group 2 - The decline in net profit is primarily due to the impact of centralized procurement in the in vitro diagnostics industry, which has pressured product prices and led to a decrease in main business revenue [6] - The company has maintained high R&D investment to enhance core competitiveness, which has contributed to the profit decline [7] - There has been a reduction in government subsidies and other non-recurring gains compared to the previous year [8]

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [13]. Core Insights - The company has been deeply engaged in the in vitro diagnostics field for thirty years, establishing a comprehensive product matrix of instruments and reagents with excellent performance. It has expanded horizontally into molecular diagnostics and biochemical diagnostics, solidifying its competitive advantage as a leader in chemiluminescence [3]. - As a pioneer in the overseas expansion of chemiluminescence, the company has seen rapid growth in overseas installations and revenue, exporting to 167 countries and establishing 14 overseas subsidiaries to enhance local operational capabilities. The report anticipates a performance acceleration phase in the next 3-5 years due to increasing domestic localization rates and faster entry into core hospitals and markets abroad [3]. Summary by Relevant Sections Chemiluminescence: Domestic and Overseas Growth - The global immunodiagnostics market is expected to grow from $18.9 billion in 2019 to $27.7 billion by 2024, with a compound annual growth rate (CAGR) of 8.0%. The Chinese market is projected to grow at a CAGR of 11.4% during the same period [8][33]. - In China, the market is expected to recover in 2026 after experiencing a decline in 2025 due to price reductions from centralized procurement and adjustments in value-added tax [8][41]. - The localization rate for chemiluminescence products has room for improvement, with over 70% already under centralized procurement. The localization rates for various categories are 66% for sex hormones, 59% for thyroid function, 53% for tumor markers, and 52% for glucose metabolism [8][47]. Product Performance and Market Share - The company maintains industry-leading product capabilities, with a coverage rate in top-tier hospitals increasing to 61%. It has developed a full range of products, including 12 models of instruments sold globally by mid-2025 [10]. - The innovative detection method has optimized reagent performance, achieving significant improvements in sensitivity and accuracy. The company’s market share in tumor markers and thyroid function projects is expected to grow significantly [10][84]. Overseas Market Localization and Growth - The company has established 14 overseas branches, focusing on localized operations. For example, in India, the company has built a robust agent network, with revenue expected to exceed 200 million yuan by 2024 [11]. - The overseas reagent segment is anticipated to be a significant growth driver, with overseas reagent revenue projected to reach 57% by 2024, compared to 80% in the domestic market [11]. Profit Forecast - The company is expected to achieve net profits of 1.65 billion yuan, 2.0 billion yuan, and 2.41 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding price-to-earnings ratios of 26X, 21X, and 18X [11].

中新网上海1月28日电 (李姝徵 狄权)不用办签证，48小时线上备案就入境；下飞机后，20多分钟就能直 达酒店……28日，快奥森多全球业务资深副总裁Bryan Hanson在上海东方枢纽国际商务合作区(以下简 称国际商务合作区)参加跨国年会时，向中新网记者表示："如此高效令人惊喜。" 图为上海东方枢纽国际商务合作区。狄权 摄 快奥森多是一家全球领先的体外诊断公司。1月26日至30日，2026快奥森多大亚太区年会在国际商务合 作区举行。这场聚集了来自11个国家、900余人的企业年会，没有繁琐的签证申请、排队通关流程，取 而代之的是"丝滑"的参会体验。这不是"专属福利"，而是国际商务合作区为全球商务人士提供的"来去 都方便"的高效体验。 作为中国首个以"最大程度便利人员跨境流动"为目标的特定政策区域，国际商务合作区允许全球各国持 有效邀请的受邀人员，免办签证等入境许可进入，一次入区可停留30天，并可根据需要申请延期。境外 人员在区内可叠加适用口岸签证、过境免签等便利化政策，从国际商务合作区进入上海市区或境内其他 地区。境内人员可以通过办理通行凭证入区。 国际商务合作区于2025年10月28日通过国家部委验收并进入 ...

Group 1 - The company expects a net profit attributable to shareholders of 180 million to 218 million yuan for the full year of 2025 [1] - The decline in profit is attributed to asset impairment provisions, with an estimated goodwill impairment provision of approximately 180 million yuan due to increased competition and policy impacts in the medical industry [1] - The company is undergoing goodwill impairment testing, which will be finalized after evaluation by qualified assessment and auditing institutions [1] Group 2 - The company's main business in the in-vitro diagnostics industry is facing pressure from policy changes, leading to a projected net profit of 360 million to 398 million yuan for 2025, a decrease of 25% to 32% year-on-year [2] - The company is actively developing its pathology business, optimizing its business structure, and enhancing its product line through new product development and cost reduction strategies [2] - Non-recurring gains and losses are expected to impact net profit by 7.07 million yuan in 2025, compared to 12.08 million yuan in the previous year [2] Group 3 - For the first three quarters of 2025, the company reported a main revenue of 1.012 billion yuan, a year-on-year decline of 18.24%, and a net profit of 272 million yuan, down 27.03% year-on-year [3] - In Q3 2025, the company’s single-quarter main revenue was 343 million yuan, a decrease of 17.39% year-on-year, with a net profit of 97.23 million yuan, down 20.96% year-on-year [3] - The company reported a debt ratio of 24.55%, with investment income of -1.04 million yuan and financial expenses of 31.04 million yuan, while maintaining a gross profit margin of 79.86% [3]

南财智讯1月28日电，九强生物发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 18,000万元—21,800万元，同比预减59.07%—66.21%；预计2025年全年归属于上市公司股东的扣除非经 常性损益的净利润为17,093万元—21,093万元，同比预减59.48%—67.16%。业绩变动原因说明：1、资 产减值计提：公司控股子公司美创公司受医疗行业政策影响，量价承压，行业竞争日益加剧，经营受到 很大影响，出于谨慎性原则，判断相关资产组商誉存在减值迹象，公司本期拟计提商誉减值准备约1.8 亿元。截至本公告披露日，相关商誉减值测试工作尚在进行中，最终商誉减值准备计提金额，将在公司 聘请的具备证券期货从业资格的评估机构及审计机构进行评估和审计的基础上，由公司履行内部的相关 程序后确定。2、主营业务影响：报告期内，公司所处体外诊断行业受政策影响，一方面增值税税率调 整影响，另一方面业务受到医疗行业政策影响，量价承压，公司盈利能力下滑，若不考虑商誉减值计提 因素，经公司测算2025年度归属于上市公司股东的净利润预计在3.6亿-3.98亿之间，预计较上年同期下 降32%—25%。公司结合自身状况 ...

Core Viewpoint - Company expects a significant decrease in net profit for 2025, projecting between RMB 40 million to 48 million, which represents a year-on-year decline of 62.23% to 68.52 due to industry pressures [1] Financial Performance - The anticipated decline in net profit is primarily attributed to the impact of centralized procurement in the in vitro diagnostic industry, leading to price pressures on the company's main products and a decrease in main business revenue [1] - The company reported a reduction in non-recurring gains such as government subsidies compared to the previous year [1] Strategic Initiatives - To enhance core competitiveness, the company maintains a high level of investment in product innovation [1] - The company adheres to a long-term operational philosophy of serving human health through leading technology and innovative products, leveraging its proprietary LiCA® technology platform [1] - The company is focused on a dual-driven strategy of import substitution and clinical interactive innovation to create high-cost performance clinical products [1] Future Outlook - The company plans to continue its innovation-driven development path, strengthen cost management, actively respond to industry changes, and steadily advance the construction of core competitiveness to achieve sustainable high-quality development [1]

报告期内，公司所处的体外诊断行业受到医保控费等行业政策影响，国内市场需求减少、价格承压。受 以上因素影响，公司营业收入出现了小幅下滑;主营业务收入尤其试剂收入的下降，导致净利润降幅略 大于营业收入降幅。 智通财经APP讯，赛科希德(688338.SH)发布2025年度业绩快报，报告期内，公司实现营业收入2.64亿 元，同比下降13.80%;实现归属于母公司所有者的净利润8714.3万元，同比下降22.88%。 ...

报告期内，公司所处的体外诊断行业受到医保控费等行业政策影响，国内市场需求减少、价格承压。受 以上因素影响，公司营业收入出现了小幅下滑；主营业务收入尤其试剂收入的下降，导致净利润降幅略 大于营业收入降幅。 格隆汇1月28日丨赛科希德(688338.SH)公布2025年度业绩快报，报告期内，公司实现营业收入2.64亿 元，同比下降13.80%；实现归属于母公司所有者的净利润8714.32万元，同比下降22.88%；实现归属于 母公司所有者的扣除非经常性损益的净利润8141.81万元，同比下降26.31%。 ...

报告期内，公司所处的体外诊断行业受到医保控费等行业政策影响，国内市场需求减少、价格承压。受 以上因素影响，公司营业收入出现了小幅下滑；主营业务收入尤其试剂收入的下降，导致净利润降幅略 大于营业收入降幅。 格隆汇1月28日丨赛科希德(688338.SH)公布2025年度业绩快报，报告期内，公司实现营业收入2.64亿 元，同比下降13.80%；实现归属于母公司所有者的净利润8714.32万元，同比下降22.88%；实现归属于 母公司所有者的扣除非经常性损益的净利润8141.81万元，同比下降26.31%。 ...